Linked Life Data

20880347

Source:http://linkedlifedata.com/resource/pubmed/id/20880347

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2010-9-30
pubmed:abstractText
To investigate whether glucose lowering with the selective sodium glucose transporter 2 (SGLT2) inhibitor dapagliflozin would prevent or reduce the decline of pancreatic function and disruption of normal islet morphology.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1463-1326
pubmed:author
pubmed:copyrightInfo
© 2010 AstraZeneca UK Ltd.
pubmed:issnType
Electronic
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1004-12
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.
pubmed:affiliation
CVGI Discovery, AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK.
pubmed:publicationType
Journal Article